UCB SA NPV News Headlines

UCBJF 
$77
*  
unch
unch
Get UCBJF Alerts
*Delayed - data as of Jan. 23, 2015  -  Find a broker to begin trading UCBJF now


Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
1/22/2015 7:00:00 PM - Zacks.com


UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
1/22/2015 7:00:00 AM - Investopedia


Immunomedics Reports Data on Oncology Candidate - Analyst Blog
1/21/2015 4:05:00 PM - Zacks.com


Immunomedics Reports Data on Oncology Candidate - Analyst Blog
1/21/2015 4:05:00 AM - Investopedia


UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog
1/19/2015 2:10:00 PM - Investopedia


UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog
1/19/2015 2:10:00 PM - Zacks.com


UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
1/9/2015 5:05:00 PM - Zacks.com


UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
1/9/2015 5:05:00 AM - Investopedia


Immunomedics: Under-Followed Company With Robust Pipeline And Huge Growth Potential
12/26/2014 5:17:00 PM - Seeking Alpha


UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
12/18/2014 3:20:00 PM - Zacks.com


UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
12/18/2014 3:20:00 AM - Investopedia


UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 - Analyst Blog
12/9/2014 2:50:00 PM - Zacks.com


UCB Presents Primary Study Results From Latest Phase 3 Brivaracetam Study
12/8/2014 1:13:00 AM - RTT News


UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog
12/1/2014 3:20:00 PM - Zacks.com


Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog
11/24/2014 4:20:00 PM - Zacks.com


Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
11/19/2014 1:00:00 AM - Zacks.com


Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
11/19/2014 1:00:00 AM - Zacks.com


Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
11/18/2014 1:00:00 PM - Investopedia


Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? - Analyst Blog
11/12/2014 5:30:00 PM - Zacks.com


UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
11/10/2014 5:30:00 PM - Zacks.com


UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
9/17/2014 5:40:00 PM - Zacks.com


Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
9/9/2014 4:20:00 PM - Zacks.com


UCB's Epilepsy Drug Vimpat's Label Expanded in the U.S. - Analyst Blog
9/2/2014 3:45:00 PM - Zacks.com


UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
8/28/2014 3:40:00 PM - Zacks.com


Drug Patent Expirations This Week: UCB, Roche's Genentech
8/8/2014 9:17:00 AM - Seeking Alpha